| cpd00122 | 2100270-37-7 | | TKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI |
cpd00123 | 2100270-36-6 | | TKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI | cpd00124 | 2100270-35-5 | | TKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI | cpd00125 | 2100270-34-4 | | TKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI | cpd00126 | 2100270-33-3 | | TKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI | cpd00127 | 2100270-32-2 | | GFLGTKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI | cpd00128 | 2100270-31-1 | | TKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI | cpd00129 | 2100270-30-0 | | TKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI | cpd00130 | 2100270-29-7 | | TKPKGTKPKGTKPKGTKPKG | N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide | Antimicrobial therapy, anti-tuberculosis | amide | European Journal of Medicinal Chemistryet.al (2017)
DOI | cpd00131 | 2133449-67-7 | | FRARXRARXRAR | Nalidixic acid | Antimicrobial therapy, antibacterial, DNA gyrase inhibition | amide | Ahmed, Marya;et.al (2017)
DOI | cpd00132 | 2133449-65-5 | | RXRXRX | Nalidixic acid | Antimicrobial drug delivery | amide | Ahmed, Marya;et.al (2017)
DOI | cpd00133 | 2133449-66-6 | | XRXRXRX | Nalidixic acid | Antimicrobial drug delivery | amide | Ahmed, Marya;et.al (2017)
DOI | cpd00134 | 2133449-64-4 | | RXRX | Nalidixic acid | Antimicrobial drug delivery | amide | Ahmed, Marya;et.al (2017)
DOI | cpd00135 | 2133449-63-3 | | XRRR | Nalidixic acid | Antimicrobial drug delivery | amide | Ahmed, Marya;et.al (2017)
DOI | cpd00136 | 2098381-23-6 | | XGLRKRLRKFRNKIKEK | 1,4,7-Triazacyclononane-1-glutaric acid-4,7-acetic acid | Antitumor therapy, MCF-7 cells | amine | Bergmann, Ralf;et.al (2017)
DOI | cpd00137 | 2098381-22-5 | | XGLRKRLRKFRNKIKEK | 1,4,7-Triazacyclononane-1-glutaric acid-4,7-acetic acid | Antitumor therapy, MCF-7 cells | amine | Bergmann, Ralf;et.al (2017)
DOI | cpd00138 | 2098389-73-0 | | XGLRKRLRKFRNKIKEK | 2-Nitro-1H-imidazole-1-acetic acid | Antitumor therapy, MCF-7 cells | amine | Bergmann, Ralf;et.al (2017)
DOI | cpd00139 | 2098389-71-8 | | XGLRKRLRKFRNKIKEK | 2-Nitro-1H-imidazole-1-acetic acid | Antitumor therapy, MCF-7 cells | amine | Bergmann, Ralf;et.al (2017)
DOI | cpd00140 | 2130904-45-7 | amyloid disrupting peptide | NFGAILSS | α-Cyano-4-hydroxycinnamic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00141 | 2130904-44-6 | amyloid disrupting peptide | NFGAILSS | α-Cyano-4-hydroxycinnamic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00142 | 2130904-43-5 | amyloid disrupting peptide | NFGAILSS | Sulfosalicylic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00143 | 2130904-42-4 | amyloid disrupting peptide | NFGAILSS | Mellitic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00144 | 2130904-41-3 | amyloid disrupting peptide | NFGAILSS | Pyromellitic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00145 | 2130904-40-2 | amyloid disrupting peptide | NFGAILSS | 4-(Chlorocarbonyl)-1,2-benzenedicarboxylic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00146 | 2130904-39-9 | amyloid disrupting peptide | NFGAILSS | 4-(Chlorocarbonyl)-1,2-benzenedicarboxylic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00147 | 2130904-38-8 | amyloid disrupting peptide | NFGAILSS | 1,3,5-Benzenetricarboxylic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00148 | 2130904-37-7 | amyloid disrupting peptide | NFGAILSS | Terephthalic acid | Type 2 diabetes therapy, amylin aggregation inhibition | amide | Profit, Adam A.et.al (2017)
DOI | cpd00149 | 2093173-45-4 | autoinducing peptide (AIP) | XAFKK | (T-4)-[2-[4-azido-1-(4-iodo-3,5-dimethyl-2H-pyrrol-2-ylidene-κN)butyl]-4-iodo-3,5-dimethyl-1H-pyrrolato-κN]difluoro-boron | Antimicrobial therapy, antibacterial (Staphylococcus aureus) | amide | Tsuchikama, Kyoji;et.al (2017)
DOI | cpd00150 | 2093173-44-3 | autoinducing peptide (AIP) | XAFKK | (T-4)-[2-[4-azido-1-(4-iodo-3,5-dimethyl-2H-pyrrol-2-ylidene-κN)butyl]-4-iodo-3,5-dimethyl-1H-pyrrolato-κN]difluoro-boron | Antimicrobial therapy, antibacterial (Staphylococcus aureus) | amide | Tsuchikama, Kyoji;et.al (2017)
DOI | cpd00151 | 2093165-92-3 | autoinducing peptide (AIP) | XAFKK | 4-Pentynoic acid | Antimicrobial therapy, antibacterial (Staphylococcus aureus) | amide | Tsuchikama, Kyoji;et.al (2017)
DOI | 
